ACELYRIN, INC.

I would now like to turn the conference call over to Tyler Marciniak, Vice President of Investor Relations and Corporate Affairs. Tyler?

Thank you, Carmen. Good afternoon, everyone, and thank you for joining us. Before we begin, I'd like to remind you that this conference call may contain forward-looking statements, such as those related to progress of our clinical trials and anticipated data readouts, our future financial and operating results, and projected cash runway. and our ability to commercialize our product candidates. These forward-looking statements involve risks and uncertainties that could cause our actual results and events to differ materially. We would urge you to review the risk factors section of our Form 10-Q for the quarter ended June 30, 2024, and additional Form 8-K that we filed with the SEC, both of which are also available on our website at acelerin.com, along with today's press release and our slide presentation. Additionally, These statements are based on information available to us today, August 13th, 2024, and we undertake no obligation to update them as circumstances may change.

The agenda for today's call is on the screen.